Ray Dalio's MRK Position Overview
Ray Dalio (via Bridgewater Associates, Lp) currently holds 30,254 shares of Merck & Co., Inc. (MRK) worth $3.89 M, representing 0.02% of the portfolio. First purchased in 2014-Q3, this long-term strategic position has been held for 41 quarters.
Based on 13F filings since 2013, Ray Dalio has maintained a long-term strategic position in MRK, representing a significant commitment to this investment thesis. Largest addition occurred in Q2 2025, adding 615,856 shares. Largest reduction occurred in Q1 2025, reducing 904,564 shares.
Analysis based on 13F filings available since 2013 Q2
Ray Dalio's Merck & Co (MRK) Holding Value Over Time
Track share changes against reported price movement
Quarterly Merck & Co (MRK) Trades by Ray Dalio
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +30,254 | New Buy | 30,254 | $128.50 |
| Q1 2026 | -310,221 | Sold Out | 0 | $0.00 |
| Q4 2025 | -203,722 | Reduce 39.64% | 310,221 | $105.26 |
| Q3 2025 | -636,779 | Reduce 55.34% | 513,943 | $83.93 |
| Q2 2025 | +615,856 | Add 115.14% | 1.15 M | $79.16 |
| Q1 2025 | -904,564 | Reduce 62.84% | 534,866 | $89.76 |
| Q4 2024 | -114,840 | Reduce 7.39% | 1.44 M | $99.48 |
| Q3 2024 | -247,721 | Reduce 13.75% | 1.55 M | $113.56 |
| Q2 2024 | -288,265 | Reduce 13.79% | 1.8 M | $123.80 |
| Q1 2024 | +133,194 | Add 6.81% | 2.09 M | $131.95 |
| Q4 2023 | +333,814 | Add 20.56% | 1.96 M | $109.02 |
| Q3 2023 | +262,304 | Add 19.27% | 1.62 M | $102.95 |
| Q2 2023 | +447,960 | Add 49.07% | 1.36 M | $115.39 |
| Q1 2023 | -20,781 | Reduce 2.23% | 912,984 | $106.39 |
| Q4 2022 | -531,637 | Reduce 36.28% | 933,765 | $110.95 |
| Q3 2022 | +147,055 | Add 11.15% | 1.47 M | $86.12 |
| Q2 2022 | +534,277 | Add 68.14% | 1.32 M | $91.17 |
| Q1 2022 | +393,728 | Add 100.87% | 784,070 | $82.05 |
| Q4 2021 | +251,339 | Add 180.82% | 390,342 | $76.64 |
| Q3 2021 | +65,706 | Add 89.64% | 139,003 | $75.11 |
| Q2 2021 | +73,297 | New Buy | 73,297 | $77.77 |
| Q2 2020 | -49,575 | Sold Out | 0 | $0.00 |
| Q1 2020 | +49,575 | New Buy | 49,575 | $73.42 |
| Q4 2019 | -8,270 | Sold Out | 0 | $0.00 |
| Q3 2019 | +8,270 | New Buy | 8,270 | $80.29 |
| Q4 2018 | -116,641 | Sold Out | 0 | $0.00 |
| Q3 2018 | -81,524 | Reduce 41.14% | 116,641 | $67.69 |
| Q2 2018 | -7,253 | Reduce 3.53% | 198,165 | $57.92 |
| Q1 2018 | +44,858 | Add 27.94% | 205,418 | $51.98 |
| Q4 2017 | +160,560 | New Buy | 160,560 | $53.69 |
| Q3 2017 | -13,862 | Sold Out | 0 | $0.00 |
| Q2 2017 | +13,862 | New Buy | 13,862 | $61.17 |
| Q3 2016 | -263,620 | Sold Out | 0 | $0.00 |
| Q2 2016 | +42,758 | Add 19.36% | 263,620 | $54.97 |
| Q1 2016 | +57,116 | Add 34.88% | 220,862 | $50.49 |
| Q4 2015 | -100,084 | Reduce 37.94% | 163,746 | $50.40 |
| Q3 2015 | +245,866 | Add 1368.66% | 263,830 | $47.13 |
| Q2 2015 | +17,964 | New Buy | 17,964 | $54.33 |
| Q1 2015 | -21,527 | Sold Out | 0 | $0.00 |
| Q4 2014 | +6,707 | Add 45.26% | 21,527 | $54.21 |
| Q3 2014 | +14,820 | New Buy | 14,820 | $56.55 |
Ray Dalio's Merck & Co Investment FAQs
Ray Dalio first purchased Merck & Co., Inc. (MRK) in Q3 2014, acquiring 14,820 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio has held Merck & Co., Inc. (MRK) for 41 quarters since Q3 2014.
Ray Dalio's largest addition to Merck & Co., Inc. (MRK) was in Q2 2025, adding 1,150,722 shares worth $91.09 M.
According to the latest 13F filing for Q2 2026, Ray Dalio's firm, Bridgewater Associates, Lp, owns 30,254 shares of Merck & Co., Inc. (MRK), valued at approximately $3.89 M.
As of the Q2 2026 filing, Merck & Co., Inc. (MRK) represents approximately 0.02% of Ray Dalio's publicly disclosed stock portfolio, making it one of their key holdings.
Ray Dalio's peak holding in Merck & Co., Inc. (MRK) was 2,090,256 shares, as reported at the end of Q1 2024.